PolyPeptide Group AG (0AAJ)
London Exchange · UK · prices in GBP · close of 19 Oct 2026
Key indicators
| Last close | GBP 43.95 |
|---|---|
| 52-week range | 21.95 – 50.00 |
| Return, 1 month / 3 months | −0.2% / +0.4% |
| Return, 1 year / 3 years | +77.8% / +156.3% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 47 |
| Volatility (1 year) | 43.7% |
| Worst drawdown (1 year) | -24.9% |
| Average daily value traded | 1.79M GBP |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
PolyPeptide Group makes peptide-based active pharmaceutical ingredients for pharmaceutical and biotechnology companies. It supplies custom and generic peptides used in medicines, serving customers that develop and manufacture drug products. The company operates manufacturing sites in Europe and North America and is based in Zug, Switzerland. Its work covers the chemical synthesis of peptides at scales ranging from research quantities to commercial production, and it also offers related analytical and regulatory support to its pharmaceutical clients.
PolyPeptide Group AG trades under the code 0AAJ on the London Exchange in UK, with its price quoted in pounds sterling (GBP). Our dividend records, which start in 2019, show payments in one calendar year. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
PolyPeptide Group AG (0AAJ) trades on the London Exchange in UK. It last closed at GBP 43.95 on 19 October 2026.
Its price-based Market X-Ray is 68 out of 100 (a fair price profile), ranking 710 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 77.8% and over the last three months it rose 0.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 81 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 19.0% | ||
| From 52-week high | -10.9% | ||
| Momentum | 79 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 0.4% | ||
| 6-month return | 27.9% | ||
| 12-month return, skipping the last month | 78.2% | ||
| Stability (higher is calmer) | 48 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 43.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -24.9% | ||
| Liquidity | 59 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.79M GBP | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 1 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −0.1% |
|---|---|
| 1 month | −0.2% |
| 3 months | +0.4% |
| 6 months | +27.9% |
| 1 year | +77.8% |
| 3 years | +156.3% |
| 5 years | – |
Signals
| 50-day / 200-day average | 44.03 / 36.94 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.16 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 28 Apr 2022 | GBX 0.0030 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.